Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol

Pharmacological Reviews

Volumn 58, Issue 1, 2006, Pages 87-114

  Pacher, Pal ^a   Nivorozhkin, Alex ^b   Szabó, Csaba ^c,d  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b Center for Integration of Medicine and Innovative Technology   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

8 [3 METHOXY 4 (PHENYLSULFINYL)PHENYL]PYRAZOLO[1,5 A][1,3,5]TRIAZIN 4 OL; ALLOPURINOL; FEBUXOSTAT; LODOXAMIDE; OXIPURINOL; PENTAERYTHRITYL TETRANITRATE; THIAZIDE DIURETIC AGENT; TUNGSTEN; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR; Y 700;

ADULT RESPIRATORY DISTRESS SYNDROME; ASEPTIC MENINGITIS; ATHEROSCLEROSIS; BIOCHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DERMATITIS; DIABETES MELLITUS; DOG; DRUG EFFECT; ENTERITIS; ENZYME STRUCTURE; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; GERBIL; GOUT; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERURICEMIA; ISCHEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY ISCHEMIA; LEUKOCYTOSIS; LIVER DYSFUNCTION; LIVER ISCHEMIA; MENINGITIS; MIDDLE CEREBRAL ARTERY OCCLUSION; NEPHRITIS; NEPHROTOXICITY; NERVOUS SYSTEM INJURY; NONHUMAN; ORGAN INJURY; PANCREATITIS; PATHOPHYSIOLOGY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RABBIT; RASH; RAT STRAIN; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SHOCK; SICKLE CELL ANEMIA; STABLE ANGINA PECTORIS; STROKE; TUMOR LYSIS SYNDROME; UVEITIS; VASCULAR DISEASE; VASCULITIS;

ALLOPURINOL; ANIMALS; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; INFLAMMATORY BOWEL DISEASES; REPERFUSION INJURY; SUPEROXIDES; XANTHINE OXIDASE;

EID: 33644631485     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.58.1.6     Document Type: Review

References (428)

1. Ahn SY, Sugi K, Talke P, Theissen JL, Linares HA, Traber LD, Herndon DN, and Traber DL (1990) Effects of allopurinol on smoke inhalation in the ovine model. J Appl Physiol 68:228-234.
2. Aiba M, Yokoyama Y, Snow TR, Novitzky D, and McKeown PP (1992) Effects of allopurinol pretreatment with pulmonary flush on lung preservation. J Heart Lung Transplant 11:1025-1030.
3. 2- generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J Clin Investig 85:739-745.
4. Akdemir H, Asik Z, Pasaoglu H, Karakucuk I, Oktem IS, and Koc RK (2001) The effect of allopurinol on focal cerebral ischaemia: an experimental study in rabbits. Neurosurg Rev 24:131-135.
5. Akizuki S, Yoshida S, Chambers DE, Eddy LJ, Parmley LF, Yellon DM, and Downey JM (1985) Infarct size limitation by the xanthine oxidase inhibitor, allopurinol, in closed-chest dogs with small infarcts. Cardiovasc Res 19:686-692.
6. Alderman M (1999) Uric acid in hypertension and cardiovascular disease. Can J Cardiol 15(Suppl F):20-22.
7. Alderman M and Aiyer KJ (2004) Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 20:369-379.
8. Alderman MH (2002) Uric acid and cardiovascular risk. Curr Opin Pharmacol 2:126-130.
9. Alderman MH, Cohen H, Madhavan S, and Kivlighn S (1999) Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34:144-150.
10. Ali S, Diwakar G, Pawa S, Siddiqui MR, Abdin MZ, Ahmad FJ, and Jain SK (2001) Xanthine oxidase-derived reactive oxygen metabolites contribute to liver necrosis: protection by 4-hydroxypyrazolo[3,4-d]pyrimidine. Biochim Biophys Acta 1536:21-30.
11. Allan G, Cambridge D, Lee-Tsang-Tan L, Van Way CW, and Whiting MV (1986) The protective action of allopurinol in an experimental model of haemorrhagic shock and reperfusion. Br J Pharmacol 89:149-155.
12. Amado LC, Saliaris AP, Raju SV, Lehrke S, St John M, Xie J, Stewart G, Fitton T, Minhas KM, Brawn J, et al. (2005) Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol 39:531-536.
13. Ames BN, Cathcart R, Schwiers E, and Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78:6858-6862.
14. Anderson RF, Hille R, and Patel KB (1995) Inactivation of xanthine oxidase by oxidative radical attack. Int J Radiat Biol 68:535-541.
15. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, et al. (2003) Uric acid and survival in chronic heart failure: validation and application in metabolic, functional and hemodynamic staging. Circulation 107:1991-1997.
16. Aoki K, Ohmori M, Takimoto M, Ota H, and Yoshida T (1997) Cocaine-induced liver injury in mice is mediated by nitric oxide and reactive oxygen species. Eur J Pharmacol 336:43-49.
17. Arai T, Mori H, Ishii H, Adachi T, Endo N, Makino K, and Mori K (1998) Oxypurinol, a xanthine oxidase inhibitor and a superoxide scavenger, did not attenuate ischemic neuronal damage in gerbils. Life Sci 63:107-112.
18. Arellano F and Sacristan JA (1993) Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 27:337-343.
19. Ashraf M and Samra ZQ (1993) Subcellular distribution of xanthine oxidase during cardiac ischemia and reperfusion: an immunocytochemical study. J Submicrosc Cytol Pathol 25:193-201.
20. Askenasy N and Navon G (1998) Intracellular volumes and membrane permeability in rat hearts during prolonged hypothermic preservation with St Thomas and University of Wisconsin solutions. J Mol Cell Cardiol 30: 1329-1339.
21. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, et al. (2001) Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 98:15215-15220.
22. Augustin AJ, Boker T, Blumenroder SH, Lutz J, and Spitznas M (1994) Free radical scavenging and antioxidant activity of allopurinol and oxypurinol in experimental lens-induced uveitis. Investig Ophthalmol Vis Sci 35:3897-3904.
23. Augustin AJ, Loeffler KU, Sekundo W, Grus FH, and Lutz J (1999) Effects of systemically applied allopurinol and prednisolone on experimental autoimmune uveitis. Graefes Arch Clin Exp Ophthalmol 237:508-512.
24. Badylak SF, Simmons A, Turek J, and Babbs CF (1987) Protection from reperfusion injury in the isolated rat heart by postischaemic deferoxamine and oxypurinol administration. Cardiovasc Res 21:500-506.
25. Bagi Z, Ungvari Z, and Koller A (2002) Xanthine oxidase-derived reactive oxygen species convert flow-induced arteriolar dilation to constriction in hyperhomocysteinemia: possible role of peroxynitrite. Arterioscler Thromb Vasc Biol 22:28-33.
26. Baker CH (1972) Protection against irreversible hemorrhagic shock by allopurinol. Proc Soc Exp Biol Med 141:694-698.
27. Battelli MG, Buonamici L, Abbondanza A, Virgili M, Contestabile A, and Stirpe F (1995) Excitotoxic increase of xanthine dehydrogenase and xanthine oxidase in the rat olfactory cortex. Brain Res Dev Brain Res 86:340-344.
28. Battelli MG, Buonamici L, Virgili M, Abbondanza A, and Contestabile A (1998) Simulated ischaemia-reperfusion conditions increase xanthine dehydrogenase and oxidase activities in rat brain slices. Neurochem Int 32:17-21.
29. Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, MacDonald P, and Joseph-Ridge N (2004) Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 8-9:1111-1116.
30. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, and Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450-2461.
31. Beetsch JW, Park TS, Dugan LL, Shah AR, and Gidday JM (1998) Xanthine oxidase-derived superoxide causes reoxygenation injury of ischemic cerebral endothelial cells. Brain Res 786:89-95.
32. Belboul A, Roberts D, Borjesson R, and Johnsson J (2001) Oxygen free radical generation in healthy blood donors and cardiac patients: the protective effect of allopurinol. Perfusion 16:59-65.
33. Ben-Hamida A, Man WK, McNeil N, and Spencer J (1998) Histamine, xanthine oxidase generated oxygen-derived free radicals and Helicobacter pylori in gastroduodenal inflammation and ulceration. Inflamm Res 47:193-199.
34. Bergsland J, LoBalsamo L, Lajos P, Feldman MJ, and Mookerjee B (1987) Allopurinol in prevention of reperfusion injury of hypoxically stored rat hearts. J Heart Transplant 6:137-140.
35. Bernard CE, Magid AA, Yen TS, and Hoener BA (1997) Mitigation of nitrofurantoin-induced toxicity in the perfused rat lung. Hum Exp Toxicol 16:727-732.
36. Berry CE and Hare JM (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol (Lond) 555: 589-606.
37. Biagi G, Giorgi I, Pacchini F, Livi O, and Scartoni V (2001) 2-Alkyloxyalkylthiohypoxanthines as new potent inhibitors of xanthine oxidase. Farmaco 56:809-813.
38. Bieber JD and Terkeltaub RA (2004) Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 50:2400-2414.
39. Biguzas M, Jablonski P, Howden BO, Thomas AC, Walls K, Scott DF, and Marshall VC (1990) Evaluation of UW solution in rat kidney preservation. II. The effect of pharmacological additives. Transplantation 49:1051-1055.
40. Bonaventura J and Gow A (2004) NO and superoxide: opposite ends of the seesaw in cardiac contractility. Proc Natl Acad Sci USA 101:16403-16404.
41. Bond RF, Haines GA, and Johnson G 3rd (1988) The effect of allopurinol and catalase on cardiovascular hemodynamics during hemorrhagic shock. Circ Shock 25:139-151.
42. Booster MH, van der Vusse GJ, Wijnen RM, Yin M, Stubenitsky BM, and Kootstra G (1994) University of Wisconsin solution is superior to histidine tryptophan ketoglutarate for preservation of ischemically damaged kidneys. Transplantation 58: 979-984.
43. Borges F, Fernandes E, and Roleira F (2002) Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem 9:195-217.
44. Boros M, Bako L, and Nagy S (1991) Effect of antioxidant therapy on cyclooxygenase-derived eicosanoid release during intestinal ischemia- reperfusion. Eur Surg Res 23:141-150.
45. Boros M, Kaszaki J, and Nagy S (1989) Oxygen free radical-induced histamine release during intestinal ischemia and reperfusion. Eur Surg Res 21:297-304.
46. Boucher F and de Leiris J (1991) Chronic administration of allopurinol fails to exert any cardioprotective effect in rats submitted to permanent coronary artery ligation. Basic Res Cardiol 86:227-235.
47. Boyer TD, Sun N, and Reynolds TB (1977) Allopurinol-hypersensitivity vasculitis and liver damage. West J Med 126:143-147.
48. Brandes RP, Kreuzer J (2005) Vascular NADPH oxidases: molecular mechanisms of activation Cardiovasc Res 65(1):16-27.
49. Brown JM, Terada LS, Grosso MA, Whitmann GJ, Velasco SE, Patt A, Harken AH, and Repine JE (1988) Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic, isolated, perfused rat hearts. J Clin Investig 81:1297-1301.
50. Budzynska A, Marek T, Nowak A, Kaczor R, and Nowakowska-Dulawa E (2001) A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 33:766-772.
51. Burton LK, Velasco SE, Patt A, Terada LS, and Repine JE (1995) Xanthine oxidase contributes to lung leak in rats subjected to skin burn. Inflammation 19:31-38.
52. Butler R, Morris AD, Belch JJ, Hill A, and Struthers AD (2000) Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35:746-751.
53. 1+ centers in molybdenum enzymes of the xanthine oxidase family: assignment of signals I and II. Biochemistry 39:2700-2707.
54. Canne C, Lowe DJ, Fetzner S, Adams B, Smith AT, Kappl R, Bray RC, and Huttermann J (1999) Kinetics and interactions of molybdenum and iron-sulfur centers in bacterial enzymes of the xanthine oxidase family: mechanistic implications. Biochemistry 38:14077-14087.
55. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, and Hare JM (2001) Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104:2407-2411.
56. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Quyyumi AA, and Panza JA (1997) Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 30:57-63.
57. Castelli P, Condemi AM, Brambillasca C, Fundaro P, Botta M, Lemma M, Vanelli P, Santoli C, Gatti S, and Riva E (1995) Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol 125:119-125.
58. Castillo M, Toledo-Pereyra LH, Gutierrez R, Prough D, and Shapiro E (1991) Peritonitis after cecal perforation: an experimental model to study the therapeutic role of antibiotics associated with allopurinol and catalase. Am Surg 57:313-316.
59. Cavallari N, Polistena A, and Cavallaro A (2000) Inability of University of Wisconsin solution to reduce postoperative peritoneal adhesions in rats. Eur J Surg 166: 650-653.
60. Cetinkale O, Senel O, and Bulan R (1999) The effect of antioxidant therapy on cell-mediated immunity following burn injury in an animal model. Burns 25:113-118.
61. Chambers DE, Parks DA, Patterson G, Roy R, McCord JM, Yoshida S, Parmley LF, and Downey JM (1985) Xanthine oxidase as a source of free radical damage in myocardial ischemia. J Mol Cell Cardiol 17:145-152.
62. Chambers DJ, Takahashi A, Humphrey SM, Harvey DM, and Hearse DJ (1992) Allopurinol-enhanced myocardial protection does not involve xanthine oxidase inhibition or purine salvage. Basic Res Cardiol 87:227-238.
63. Charlat MI, O'Neill PG, Egan JM, Abernethy DR, Michael LH, Myers ML, Roberts R, and Bolli R (1987) Evidence for a pathogenetic role of xanthine oxidase in the "stunned" myocardium. Am J Physiol 252:H566-H577.
64. Choi HK and Curhan G (2005) Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 17:341-345.
65. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Zeni P, and Zardini P (2002) Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J 143:1107-1111.
66. Clark DA, Fornabaio DM, McNeill H, Mullane KM, Caravella SJ, and Miller MJ (1988) Contribution of oxygen-derived free radicals to experimental necrotizing enterocolitis. Am J Pathol 130:537-542.
67. Coetzee A, Roussouw G, and Macgregor L (1996) Failure of allopurinol to improve left ventricular stroke work after cardiopulmonary bypass surgery. J Cardiothorac Vasc Anesth 10:627-633.
68. Coghlan JG, Flitter WD, Clutton SM, Panda R, Daly R, Wright G, Ilsley CD, and Slater TF (1994) Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 107:248-256.
69. Crowell JW, Jones CE, and Smith EE (1969) Effect of allopurinol on hemorrhagic shock. Am J Physiol 216:744-748.
70. Csiszar A, Ungvari Z, Edwards JG, Kaminski P, Wolin MS, Koller A, and Kaley G (2002) Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res 90:1159-1166.
71. Cunningham SK and Keaveny TV (1978) Effect of a xanthine oxidase inhibitor on adenine nucleotide degradation in hemorrhagic shock. Eur Surg Res 10:305-313.
72. Czako L, Takacs T, Varga IS, Tiszlavicz L, Hai DQ, Hegyi P, Matkovics B, and Lonovics J (2000) Oxidative stress in distant organs and the effects of allopurinol during experimental acute pancreatitis. Int J Pancreatol 27:209-216.
73. Das DK, Engelman RM, Clement R, Otani H, Prasad MR, and Rao PS (1987) Role of xanthine oxidase inhibitor as free radical scavenger: a novel mechanism of action of allopurinol and oxypurinol in myocardial salvage. Biochem Biophys Res Commun 148:314-319.
74. Davis JC Jr (1999) A practical approach to gout: Current management of an 'old' disease. Postgrad Med 106:115-116, 119-123.
75. de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, Sharma HS, and Ceconi C (2000) Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol 32:2083-2089.
76. Deitch EA, Bridges W, Baker J, Ma JW, Ma L, Grisham MB, Granger DN, Specian RD, and Berg R (1988) Hemorrhagic shock-induced bacterial translocation is reduced by xanthine oxidase inhibition or inactivation. Surgery 104:191-198.
77. Deliconstantinos G, Villiotou V, and Stavrides JC (1996) Alterations of nitric oxide synthase and xanthine oxidase activities of human keratinocytes by ultraviolet B radiation: potential role for peroxynitrite in skin inflammation. Biochem Pharmacol 51:1727-1738.
78. Desco MC, Asensi M, Marquez R, Martinez-Valls J, Vento M, Pallardo FV, Sastre J, and Vina J (2002) Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 51:1118-1124.
79. Desole MS, Esposito G, Fresu L, Migheli R, Sircana S, Delogu R, Miele M, and Miele E (1996) Further investigation of allopurinol effects on MPTP-induced oxidative stress in the striatum and brain stem of the rat. Pharmacol Biochem Behav 54:377-383.
80. Doehner W and Anker SD (2005a) Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart 91:707-709.
81. Doehner W and Anker SD (2005b) Uric acid in chronic heart failure. Semin Nephrol 25:61-66.
82. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, and Hambrecht R (2002) Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105:2619-2624.
83. Dorion D, Zhong A, Chiu C, Forrest CR, Boyd B, and Pang CY (1993) Role of xanthine oxidase in reperfusion injury of ischemic skeletal muscles in the pig and human. J Appl Physiol 75:246-255.
84. Downey JM, Miura T, Eddy LJ, Chambers DE, Mellert T, Hearse DJ, and Yellon DM (1987) Xanthine oxidase is not a source of free radicals in the ischemic rabbit heart. J Mol Cell Cardiol 19:1053-1060.
85. Duchene DA, Smith CP, and Goldfarb RA (2000) Allopurinol induced meningitis. J Urol 164:2028.
86. Duncan JG, Ravi R, Stull LB, and Murphy AM (2005) Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy. Am J Physiol Heart Circ Physiol 289:H1512-H1528.
87. Eger BT, Okamoto K, Enroth C, Sato M, Nishino T, Pai EF, and Nishino T (2000) Purification, crystallization and preliminary X-ray diffraction studies of xanthine dehydrogenase and xanthine oxidase isolated from bovine milk. Acta Crystallogr D Biol Crystallogr 56:1656-1658.
88. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, Kass DA, Marban E, and Hare JM (1999) Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 85:437-445.
89. Elion GB (1988) The purine path to chemotherapy. Nobel lecture. Burroughs Wellcome Co., Research Triangle Park, NC
90. Elion GB (1993) The quest for a cure. Annu Rev Pharmacol Toxicol 33:1-23.
91. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Muller M, Fuchs M, Hilfiker-Kleiner D, Hornig B, Drexler H, et al. (2004) Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110:2175-2179.
92. Engerson TD, McKelvey TG, Rhyne DB, Boggio EB, Snyder SJ, and Jones HP (1987) Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues. J Clin Investig 79:1564-1570.
93. Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, and Pai EF (2000) Crystal structure of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion. Proc Natl Acad Sci USA 97:10723-10728.
94. Fam AG (2001) Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 3:29-35.
95. Farquharson CA, Butler R, Hill A, Belch JJ, and Struthers AD (2002) Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106:221-226.
96. Ferdinandy P, Danial H, Ambrus I, Rothery RA, and Schulz R (2000) Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87:241-247.
97. Ferdinandy P, Panas D, and Schulz R (1999) Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. Am J Physiol 276: H1861-H1867.
98. Flynn WJ Jr, Pilati D, and Hoover EL (1997) Xanthine oxidase inhibition prevents mesenteric blood flow deficits after resuscitated hemorrhagic shock by preserving endothelial function. J Surg Res 68:175-180.
99. Flynn WJ Jr, Pilati D, and Hoover EL (1999) Effect of allopurinol on venous endothelial dysfunction after resuscitated hemorrhagic shock. Int J Surg Investig 1:11-18.
100. Folch E, Gelpi E, Rosello-Catafau J, and Closa D (2001) Free radicals generated by xanthine oxidase mediate pancreatitis-associated organ failure. Dig Dis Sci 276: 14359-14365.
101. Frederiks WM and Bosch KS (1996) The proportion of xanthine oxidase activity of total xanthine oxidoreductase activity in situ remains constant in rat liver under various (patho)physiological conditions. Hepatology 24:1179-1184.
102. Freudenberger RS, Schwarz RP Jr, Brown J, Moore A, Mann D, Givertz MM, Colucci WS, and Hare JM (2004) Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure. Expert Opin Investig Drugs 13:1509-1516.
103. Fukahori M, Ichimori K, Ishida H, Nakagawa H, and Okino H (1994) Nitric oxide reversibly suppresses xanthine oxidase activity. Free Radic Res 21:203-212.
104. Fukunari A, Okamoto K, Nishino T, Eger BT, Pai EF, Kamezawa M, Yamada I, and Kato N (2004) Y-700 [1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole- 4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion. J Pharmacol Exp Ther 311:519-528.
105. Garcia Garcia J, Martin Rollan C, Refoyo Enrinquez MA, Holgado Madruga M, Marino, Hernandez E, Macias Nunez JF, Gomez Alonso A (1990) Improved survival in intestinal ischemia by allopurinol not related to xanthine-oxidase inhibition. J Surg Res 48:144-146.
106. Gavin AD and Struthers AD (2005) Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91:749-753.
107. Ghio AJ, Kennedy TP, Stonehuerner J, Carter JD, Skinner KA, Parks DA, and Hoidal JR (2002) Iron regulates xanthine oxidase activity in the lung. Am J Physiol 283:L563-L572.
108. Ghio AJ, Kennedy TP, Stonehuerner J, Carter JD, Skinner KA, Parks DA., Hoidal JR, Giler S, Eshel Y, Pinkhas J, et al. (1977) Elevation of serum xanthine oxidase activity following halothane anesthesia in man. Experientia (Basel) 33:1356-1358.
109. Giler S, Eshel Y, Pinkhas J, Ventura E, Levy E, Urea I, Sperling O, and de Vries A (1977) Elevation of serum xanthine oxidase activity following halothane anesthesia in man. Experientia 33:1356-1358.
110. Giler S, Ventura E, Levy E, Urca I, Sperling O, and de Vries A (1976) Elevation of serum xanthine oxidase following halothane anesthesia in the rat. Experientia (Basel) 32:620-621.
111. Godber BL, Doel JJ, Goult TA, Eisenthal R, and Harrison R (2001) Suicide inactivation of xanthine oxidoreductase during reduction of inorganic nitrite to nitric oxide. Biochem J 358:325-333.
112. Godber BL, Doel JJ, Sapkota GP, Blake DR, Stevens CR, Eisenthal R, and Harrison R (2000) Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol Chem 275:7757-7763.
113. Godber BL, Schwarz G, Mendel RR, Lowe DJ, Bray RC, Eisenthal R, and Harrison R (2005) Molecular characterization of human xanthine oxidoreductase: the enzyme is grossly deficient in molybdenum and substantially deficient in iron-sulphur centres. Biochem J 388:501-508.
114. Godin DV and Bhimji S (1987) Effects of allopurinol on myocardial ischemic injury induced by coronary artery ligation and reperfusion. Biochem Pharmacol 36:2101-2107.
115. Godin DV and Garnett ME (1989) Altered antioxidant status in the ischemic/reperfused rabbit myocardium: effects of allopurinol. Can J Cardiol 5:365-371.
116. Godin DV, Bhimji S, and McNeill JH (1986) Effects of allopurinol pretreatment on myocardial ultrastructure and arrhythmias following coronary artery occlusion and reperfusion. Virchows Arch B Cell Pathol Incl Mol Pathol 52:327-341.
117. Granger DN, McCord JM, Parks DA, and Hollwarth ME (1986) Xanthine oxidase inhibitors attenuate ischemia-induced vascular permeability changes in the cat intestine. Gastroenterology 90:80-84.
118. Granger DN, Rutili G, and McCord JM (1981) Superoxide radicals in feline intestinal ischemia. Gastroenterology 81:22-29.
119. Greenberg LE, Nguyen T, and Miller SM (2001) Suspected allopurinol-induced aseptic meningitis. Pharmacotherapy 21:1007-1009.
120. Griendling KK (2004) Novel NAD(P)H oxidases in the cardiovascular system. Heart 90:491-493.
121. Grisham MB, Hernandez LA, and Granger DN (1986) Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol 251:G567-G574.
122. Grum CM, Ketai LH, Myers CL, and Shlafer M (1987) Purine efflux after cardiac ischemia: relevance to allopurinol cardioprotection. Am J Physiol 252:H368-H373.
123. Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, Iwasa A, Fujita N, Kudo S, Ohkubo T, et al. (2003) Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol 41:699-705.
124. 31P NMR spectroscopy, biochemical assays and light microscopy. Transplantation 54:599-603.
125. Guthikonda S, Sinkey C, Barenz T, and Haynes WG (2003) Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 107:416-421.
126. Guthikonda S, Woods K, Sinkey CA, and Haynes WG (2004) Role of xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers. Am J Cardiol 93:664-668.
127. Gwinner W, Plasger J, Brandes RP, Kubat B, Schulze M, Regele H, Kerjaschki D, Olbricht CJ, and Koch KM (1999) Role of xanthine oxidase in passive Heymann nephritis in rats. J Am Soc Nephrol 10:538-544.
128. Hakguder G, Akgur FM, Ates O, Olguner M, Aktug T, and Ozer E (2002) Short-term intestinal ischemia-reperfusion alters intestinal motility that can be preserved by xanthine oxidase inhibition. Dig Dis Sci 47:1279-1283.
129. Hare JM (2003) Nitric oxide and excitation-contraction coupling. J Mol Cell Cardiol 35:719-729.
130. Harrison R (2002) Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33:774-797.
131. Harrison R (2004) Physiological roles of xanthine oxidoreductase. Drug Metab Rev 36:363-375.
132. Hashimoto T, Fukunari A, Yamada I, Yanaka N, Chen D, and Kato N (2005) Y-700, a novel inhibitor of xanthine oxidase, suppresses the development of colon aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine- treated mice. Biosci Biotechnol Biochem 69:209-211.
133. Hassoun PM, Yu FS, Cote CG, Zulueta JJ, Sawhney R, Skinner KA, Skinner HB, Parks DA, and Lanzillo JJ (1998) Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1 and hypoxia: role in acute lung injury. Am J Respir Crit Care Med 158:299-305.
134. Hassoun PM, Yu FS, Zulueta JJ, White AC, and Lanzillo JJ (1995) Effect of nitric oxide and cell redox status on the regulation of endothelial cell xanthine dehydrogenase. Am J Physiol 268:L809-L817.
135. Headrick JP, Armiger LC, and Willis RJ (1990) Behaviour of energy metabolites and effect of allopurinol in the "stunned" isovolumic rat heart. J Mol Cell Cardiol 22:1107-1116.
136. Hearse DJ, Manning AS, Downey JM, and Yellon DM (1986) Xanthine oxidase: a critical mediator of myocardial injury during ischemia and reperfusion? Acta Physiol Scand Suppl 548:65-78.
137. Hegge JO, Southard JH, and Haworth RA (2001) Preservation of metabolic reserves and function after storage of myocytes in hypothermic UW solution. Am J Physiol 281:C758-C772.
138. Hestin D and Johns EJ (1999) The influence of allopurinol on kidney haemodynamic and excretory responses to renal ischaemia in anaesthetized rats. Br J Pharmacol 128:255-261.
139. Hille R (1996) The mononuclear molybdenum enzymes. Chem Rev 96:2757-2816.
140. Hitchings GH and Elion GB (1963) Chemical suppression of the immune response. Pharmacol Rev 15:365-405.
141. - in the chemiluminescence of luminol. Photochem Photobiol. 18:451-455.
142. Hoidal JR, Xu P, Huecksteadt T, Sanders KA, and Pfeffer K (1997) Transcriptional regulation of human xanthine dehydrogenase/xanthine oxidase. Biochem Soc Trans 25:796-799.
143. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, and Koprowski H (1998) Uric acid, a natural scavenger of peroxynitrite in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95:675-680.
144. Hopkins RW, Abraham J, Simeone FA, and Damewood CA (1975) Effects of allopurinol on hepatic adenosine nucleotides in hemorrhagic shock. J Surg Res 19: 381-390.
145. Hopson SB, Lust RM, Sun YS, Zeri RS, Morrison RF, Otaki M, and Chitwood WR Jr (1995) Allopurinol improves myocardial reperfusion injury in a xanthine oxidase-free model. J Natl Med Assoc 87:480-484.
146. Horiuchi H, Ota M, Kaneko H, Kasahara Y, Ohta T, and Komoriya K (1999c) Nephrotoxic effects of allopurinol in dinitrofluorobenzene-sensitized mice: comparative studies on TEI-6720. Res Commun Mol Pathol Pharmacol 104:293-305.
147. Horiuchi H, Ota M, Kitahara S, Ohta T, Kiyoki M, and Komoriya K (1999a) Allopurinol increases ear swelling and mortality in a dinitrofluorobenzene- induced contact hypersensitivity mouse model. Biol Pharm Bull 22:810-815.
148. Horiuchi H, Ota M, Kobayashi M, Kaneko H, Kasahara Y, Nishimura S, Kondo S, and Komoriya K (1999b) A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol 104:307-319.
149. Horiuchi H, Ota M, Nishimura S, Kaneko H, Kasahara Y, Ohta T, and Komoriya K (2000) Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Sci 66:2051-2070.
150. Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, and Hosoya T (2004) PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 23:1117-1118.
151. Houston M, Chumley P, Radi R, Rubbo H, and Freeman BA (1998) Xanthine oxidase reaction with nitric oxide and peroxynitrite. Arch Biochem Biophys 355:1-8.
152. Houston M, Estevez A, Chumley P, Aslan M, Marklund S, Parks DA, and Freeman BA (1999) Binding of xanthine oxidase to vascular endothelium: kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem 274:4985-4994.
153. Ichimori K, Fukahori M, Nakazawa H, Okamoto K, and Nishino T (1999) Inhibition of xanthine oxidase and xanthine dehydrogenase by nitric oxide: nitric oxide converts reduced xanthine-oxidizing enzymes into the desulfo-type inactive form. J Biol Chem 274:7763-7768.
154. Ikeda T, Shimokata K, Daikoku T, Fukatsu T, Tsutsui Y, and Nishiyama Y (1992) Pathogenesis of cytomegalovirus-associated pneumonitis in ICR mice: possible involvement of superoxide radicals. Arch Virol 127:11-24.
155. Ilich P and Hille R (2002) Oxo, sulfido and tellurido Mo-enedithiolate models for xanthine oxidase: understanding the basis of enzyme reactivity. J Am Chem Soc 124:6796-6797.
156. Ishibuchi S, Morimoto H, Oe T, Ikebe T, Inoue H, Fukunari A, Kamezawa M, Yamada I, and Naka Y (2001) Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. Bioorg Med Chem Lett 11:879-882.
157. Itoh T, Kawakami M, Yamauchi Y, Shimizu S, and Nakamura M (1986) Effect of allopurinol on ischemia and reperfusion-induced cerebral injury in spontaneously hypertensive rats. Stroke 17:1284-1287.
158. Janssen M, de Jong JW, Pasini E, and Ferrari R (1993) Myocardial xanthine oxidoreductase activity in hypertensive and hypercholesterolemic rats. Cardioscience 4:25-29.
159. Jarnerot G, Strom M, Danielsson A, Kilander A, Loof L, Hultcrantz R, Lofberg R, Floren C, Nilsson A, and Brostrom O (2000) Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis. Aliment Pharmacol Ther 14:1159-1162.
160. Jarzobski J, Ferry J, Wombolt D, Fitch DM, and Egan JD (1970) Vasculitis with allopurinol therapy. Am Heart J 79:116-121.
161. Johnson WD, Kayser KL, Brenowitz JB, and Saedi SF (1991) A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 121:20-24.
162. Kakita T, Suzuki M, Takeuchi H, Unno M, and Matsuno S (2002) Significance of xanthine oxidase in the production of intracellular oxygen radicals in an in-vitro hypoxia-reoxygenation model. J Hepatobiliary Pancreat Surg 9:249-255.
163. Kaliakin IE and Mit'kin AF (1993) Effects of allopurinol on uric acid metabolism and lipid peroxidation in ischemic heart disease patients with stable angina. Kardiologiia 33:15-17.
164. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, and McCann WP (1998) Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 32:64-71.
165. Kawashima Y, Takeyoshi I, Furukawa H, Lee RG, Starzl TE, and Todo S (1999) Cold preservation of the human colon and ileum with University of Wisconsin solution. Clin Transplant 13: 420-425.
166. Kayyali US, Budhiraja R, Pennella CM, Cooray S, Lanzillo JJ, Chalkley R, and Hassoun PM (2003) Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol Appl Pharmacol 188:59-68.
167. Kayyali US, Donaldson C, Huang H, Abdelnour R, and Hassoun PM (1998) Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia. J Biol Chem 43:2405-2410.
168. Keshavarzian A, Morgan G, Sedghi S, Gordon JH, and Doria M (1990) Role of reactive oxygen metabolites in experimental colitis. Gut 31:786-790.
169. Khadour FH, Panas D, Ferdinandy P, Schulze C, Csont T, Lalu MM, Wildhirt SM, and Schulz R (2002) Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. Am J Physiol 283:H108-H115.
170. 2+ cycling. Curr Opin Drug Discov Devel 6:658-666.
171. Khan SA, Lee K, Minhas KM, Gonzalez DR, Raju SV, Tejani AD, Li D, Berkowitz DE, and Hare JM (2004) Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci USA 101:15944-15948.
172. Khan SA, Skaf MW, Harrison RW, Lee K, Minhas KM, Kumar A, Fradley M, Shoukas AA, Berkowitz DE, and Hare JM (2003) Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases. Circ Res 92:1322-1329.
173. Khoo BP and Leow YH (2000) A review of inpatients with adverse drug reactions to allopurinol. Singapore Med J 41:156-160.
174. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, and Johnson RJ (2005) Hyperuricemia -induces endothelial dysfunction. Kidney Int 67:1739-1742.
175. Kingma JG Jr, Denniss AR, Hearse DJ, Downey JM, and Yellon DM (1987) Limitation of infarct size for 24 hours by combined treatment with allopurinol plus verapamil during acute myocardial infarction in the dog. Circulation 75:V25-V33.
176. Kingma JG Jr, Denniss AR, and Yellon DM (1989) Influence of allopurinol plus verapamil treatment on myocardial tissue necrosis during permanent coronary occlusion in canine hearts with small infarcts. J Cardiovasc Pharmacol 14:6-13.
177. Kingma JG Jr, Miura T, Downey JM, Hearse DJ, and Yellon DM (1988) Myocardial salvage with allopurinol during 24 h of permanent coronary occlusion: importance of pretreatment. Can J Cardiol 4:360-365.
178. Kinnula VL, Sarnesto A, Heikkila L, Toivonen H, Mattila S, and Raivio KO (1997) Assessment of xanthine oxidase in human lung and lung transplantation. Eur Respir J 10:676-680.
179. Kinsman JM 3rd; Murry CE, Richard VJ, Jennings RB, and Reimer KA (1988) The xanthine oxidase inhibitor oxypurinol does not limit infarct size in a canine model of 40 minutes of ischemia with reperfusion. J Am Coll Cardiol 12:209-217.
180. Kinugasa Y, Ogino K, Furuse Y, Shiomi T, Tsutsui H, Yamamoto T, Igawa O, Hisatome I, and Shigemasa C (2003) Allopurinol improves cardiac dysfunction after ischemia-reperfusion via reduction of oxidative stress in isolated perfused rat hearts. Circ J 67:781-787.
181. Kinugawa S, Huang H, Wang Z, Kaminski PM, Wolin MS, and Hintze TH (2005) A defect of neuronal nitric oxide synthase increases xanthine oxidase-derived superoxide anion and attenuates the control of myocardial oxygen consumption by nitric oxide derived from endothelial nitric oxide synthase. Circ Res 96:355-362.
182. Kitazawa Y, Matsubara M, Takeyama N, and Tanaka T (1991) The role of xanthine oxidase in paraquat intoxication. Arch Biochem Biophys 288:220-224.
183. Kittleson MM and Hare JM (2005) Xanthine oxidase inhibitors: an emerging class of drugs for heart failure. Eur Heart J 26:1458-1460.
184. Knight TR, Kurtz A, Bajt ML, Hinson JA, and Jaeschke H (2001) Vascular and hepatocellular peroxynitrite formation during acetaminophen toxicity: role of mitochondrial oxidant stress. Toxicol Sci 62:212-220.
185. Kögler H, Fraser H, McCune S, Altschuld R, and Marban E (2003) Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res 59:582-592.
186. Komaki Y, Sugiura H, Koarai A, Tomaki M, Ogawa H, Akita T, Hattori T, and Ichinose M (2005) Cytokine-mediated xanthine oxidase upregulation in chronic obstructive pulmonary disease's airways. Pulm Pharmacol Ther 18:297-302.
187. Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, Nakachi T, Yamanaka H, and Kamatani N (2004) Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 23:1119-1122.
188. Kono H, Rusyn I, Bradford BU, Connor HD, Mason RP, and Thurman RG (2000) Allopurinol prevents early alcohol-induced liver injury in rats. J Pharmacol Exp Ther 293:296-303.
189. Konya L, Kekesi V, Nagy SJ, and Feher J (1993) Effect of antioxidant treatment on the myocardium during reperfusion in dogs. Acta Physiol Hung 81:219-228.
190. Kooy NW, Royall JA, Ischiropoulos H, and Beckman JS (1994) Peroxynitrite-mediated oxidation of dihydrorhodamine 123. Free Radic Biol Med 16:149-156.
191. Kramer HM and Curhan G (2002) The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 40:37-42.
192. Kulah B, Besler HT, Akdag M, Oruc T, Altinok G, Kulacoglu H, Ozmen MM, and Coskun F (2004) The effects of verapamil vs. allopurinol on intestinal ischemia/reperfusion injury in rats: "an experimental study." Hepatogastroenterology 51: 401-407.
193. Kuwabara Y, Nishino T, Okamoto K, Matsumura T, Eger BT, Pai EF, and Nishino T (2003) Unique amino acids cluster for switching from the dehydrogenase to oxidase form of xanthine oxidoreductase. Proc Natl Acad Sci USA 100:8170-8175.
194. Kuzmin AI, Tskitishvili OV, Serebryakova LI, Kapelko VI, Majorova IV, and Medvedev OS (1995) Allopurinol: kinetics, inhibition of xanthine oxidase activity and protective effect in ischemic-reperfused canine heart as studied by cardiac microdialysis. J Cardiovasc Pharmacol 25:564-571.
195. Laakso J, Mervaala E, Himberg JJ, Teravainen TL, Karppanen H, Vapaatalo H, and Lapatto R (1998) Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension 32:902-906.
196. Laakso JT, Teravainen TL, Martelin E, Vaskonen T, and Lapatto R (2004) Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens 22:1333-1340.
197. Landmesser U and Drexler H (2002) Allopurinol and endothelial function in heart failure: future or fantasy? Circulation 106:173-175.
198. Lasley RD, Ely SW, Berne RM, and Mentzer RM Jr (1988) Allopurinol enhanced adenine nucleotide repletion after myocardial ischemia in the isolated rat heart. J Clin Investig 81:16-20.
199. Lazarus HM, Owens ML, and Hopfenbeck A (1974) Allopurinol protection of hepatic nuclear function during hemorrhagic shock. Surg Forum 25:10-12.
200. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, Poole-Wilson PA, and Coats AJ (1998) Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 19:1814-1822.
201. Li GR and Ferrier GR (1992) Effects of allopurinol on reperfusion arrhythmias in isolated ventricles. Am J Physiol 263:H341-H348.
202. Li JM and Shah AM (2004) Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol 287:R1014-R1030.
203. Lieber CS (1997) Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Adv Pharmacol 38:601-628.
204. Lin LN, Wang WT, Wu JZ, Hu ZY, and Xie KJ (2004) Protective effect of propofol on liver during ischemia-reperfusion injury in patients undergoing liver surgery. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 16:42-44.
205. Lin Y and Phillis JW (1991) Oxypurinol reduces focal ischemic brain injury in the rat. Neurosci Lett 126:187-190.
206. Lin Y and Phillis JW (1992) Deoxycoformycin and oxypurinol: protection against focal ischemic brain injury in the rat. Brain Res 571:272-280.
207. Linas SL, Whittenburg D, and Repine JE (1990) Role of xanthine oxidase in ischemia/reperfusion injury. Am J Physiol 258:F711-F716.
208. Linder N, Rapola J, and Raivio KO (1999) Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Investig 79:967-974.
209. Lindsay S, Liu TH, Xu JA, Marshall PA, Thompson JK, Parks DA, Freeman BA, Hsu CY, and Beckman JS (1991) Role of xanthine dehydrogenase and oxidase in focal cerebral ischemic injury to rat. Am J Physiol 261:H2051-H2057.
210. Liu W, Rosenberg GA, Shi H, Furuichi T, Timmins GS, Cunningham LA, and Liu KJ (2004) Xanthine oxidase activates pro-matrix metalloproteinase-2 in cultured rat vascular smooth muscle cells through non-free radical mechanisms. Arch Biochem Biophys 426:11-17.
211. Lochner F, Sangiah S, Burrows G, Shawley R, McNew R, and Walker J (1989) Effects of allopurinol in experimental endotoxin shock in horses. Res Vet Sci 47:178-184.
212. Lynch ED, Gu R, Pierce C, and Kil J (2005) Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 201:81-89.
213. Lynch MJ, Grum CM, Gallagher KP, Bolling SF, Deeb GM, and Morganroth ML (1988) Xanthine oxidase inhibition attenuates ischemic-reperfusion lung injury. J Surg Res 44:538-544.
214. Mabley JG, Nivorozhkin A, Southan GJ, Szabó C, and Salzman AL (2003): Pathogenetic role of xanthine oxidase in a murine model of acute lung injury. FASEB J 17:A247.
215. MacGowan SW, Regan MC, Malone C, Sharkey O, Young L, Gorey TF, and Wood AE (1995) Superoxide radical and xanthine oxidoreductase activity in the human heart during cardiac operations. Ann Thorac Surg 60:1289-1293.
216. Mainous MR, Xu D, and Deitch EA (1993) Role of xanthine oxidase and prostaglandins in inflammatory-induced bacterial translocation. Circ Shock 40:99-104.
217. Malkiel S, Har-el R, Schwalb H, Uretzky G, Borman JB, and Chevion M (1993) Interaction between allopurinol and copper: possible role in myocardial protection. Free Radic Res Commun 18:7-15.
218. Manning AS, Coltart DJ, and Hearse DJ (1984) Ischemia and reperfusion-induced arrhythmias in the rat: effects of xanthine oxidase inhibition with allopurinol. Circ Res 55:545-548.
219. Martin HM, Hancock JT, Salisbury V, and Harrison R (2004) Role of xanthine oxidoreductase as an antimicrobial agent. Infect Immun 72:4933-4939.
220. Martz D, Rayos G, Schielke GP, and Betz AL (1989) Allopurinol and dimethylthiourea reduce brain infarction following middle cerebral artery occlusion in rats. Stroke 20:488-494.
221. Matsui N, Satsuki I, Morita Y, Inaizumi K, Kasajima K, Kanoh R, Fukuishi N, and Akagi M (2000) Xanthine oxidase-derived reactive oxygen species activate nuclear factor κB during hepatic ischemia in rats. Jpn J Pharmacol 84:363-366.
222. Matsuki T, Shirato C, Cohen MV, and Downey JM (1990) Oxypurinol limits myocardial infarct size in closed chest dogs without pretreatment. Can J Cardiol 6:123-129.
223. Matsumoto S, Koshiishi I, Inoguchi T, Nawata H, and Utsumi H (2003) Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice. Free Radic Res 37:767-772.
224. Matsumura F, Yamaguchi Y, Goto M, Ichiguchi O, Akizuki E, Matsuda T, Okabe K, Liang J, Ohshiro H, Iwamoto T, et al. (1998) Xanthine oxidase inhibition attenuates kupffer cell production of neutrophil chemoattractant following ischemia-reperfusion in rat liver. Hepatology 28:1578-1587.
225. Maurer HS, Steinherz PG, Gaynon PS, Finklestein JZ, Sather HN, Reaman GH, Bleyer WA, and Hammond GD (1988) The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. J Clin Oncol 6:1425-1432.
226. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, and Mulford DJ (2005) Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 12:22-34.
227. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, and Johnson RJ (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101-1106.
228. McCarthy GM, Barthelemy CR, Veum JA, and Wortmann RL (1991) Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 34:1489-1494.
229. McCord JM (1985) Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 17, 312:159-163.
230. McCord JM and Fridovich I (1968) The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem 243:5753-5760.
231. McCord JM and Fridovich I (1969) Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244:6049-6055.
232. McKechnie K, Furman BL, and Parratt JR (1986) Modification by oxygen free radical scavengers of the metabolic and cardiovascular effects of endotoxin infusion in conscious rats. Circ Shock 19:429-439.
233. McKelvey TG, Hollwarth ME, Granger DN, Engerson TD, Landler U, and Jones HP (1988) Mechanisms of conversion of xanthine dehydrogenase to xanthine oxidase in ischemic rat liver and kidney. Am J Physiol 254:G753-G760.
234. McManaman JL and Bain DL (2002) Structural and conformational analysis of the oxidase to dehydrogenase conversion of xanthine oxidoreductase. J Biol Chem 277:21261-21268.
235. McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, Jo H, and Harrison DG (2003) Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol 285:H2290-H2297.
236. McNally JS, Saxena A, Cai H, Dikalov S, and Harrison DG (2005) Regulation of xanthine oxidoreductase protein expression by hydrogen peroxide and calcium. Arterioscler Thromb Vasc Biol 25:1623-1628.
237. Megison SM, Horton JW, Chao H, and Walker PB (1990) High dose versus low dose enteral allopurinol for prophylaxis in mesenteric ischemia. Circ Shock 30:323-329.
238. Mellin V, Isabelle M, Oudot A, Vergely-Vandriesse C, Monteil C, Di Meglio B, Henry JP, Dautreaux B, Rochette L, Thuillez C, et al. (2005) Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 15:1544-1550.
239. Meneshian A and Bulkley GB (2002) The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation 9:161-175.
240. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, and Rosano GM (2004) Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 94:93293-93295.
241. Mervaala EM, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, Vapaatalo H, Muller DN, Fiebeler A, Ganten U, Ganten D, et al. (2001) Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 37:414-418.
242. Metzger J, Dore SP, and Lauterburg BH (1988) Oxidant stress during reperfusion of ischemic liver: no evidence for a role of xanthine oxidase. Hepatology 8:580-584.
243. Miele M, Esposito G, Migheli R, Sircana S, Zangani D, Fresu GL, and Desole MS (1995) Effects of allopurinol on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced neurochemical changes in the striatum and in the brainstem of the rat. Neurosci Lett 3:155-159.
244. Miesel R and Zuber M (1993) Elevated levels of xanthine oxidase in serum of patients with inflammatory and autoimmune rheumatic diseases. Inflammation 17:551-561.
245. Miesel R, Zuber M, Sanocka D, Graetz R, and Kroeger H (1994) Effects of allopurinol on in vivo suppression of arthritis in mice and ex vivo modulation of phagocytic production of oxygen radicals in whole human blood. Inflammation 18:597-612.
246. Millar TM, Kanczler JM, Bodamyali T, Blake DR, and Stevens CR (2002) Xanthine oxidase is a peroxynitrite synthase: newly identified roles for a very old enzyme. Redox Rep 7:65-70.
247. Millar TM, Stevens CR, Benjamin N, Eisenthal R, Harrison R, and Blake DR (1998) Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett 427:225-228.
248. Minhas KM, Saraiva RM, Schuleri KH, Lehrke S, Zheng M, Saliaris AP, Berry CE, Vandegaer KM, Li D, and Hare JM (2006) Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res, in press.
249. Miura T, Yellon DM, Kingma J, and Downey JM (1988) Protection afforded by allopurinol in the first 24 hours of coronary occlusion is diminished after 48 hours. Free Radic Biol Med 4:25-30.
250. Miyakawa H, Sato K, Shinbori T, Okamoto T, Gushima Y, Fujiki M, and Suga M (2002) Effects of inducible nitric oxide synthase and xanthine oxidase inhibitors on SEB-induced interstitial pneumonia in mice. Eur Respir J 19:447-457.
251. Miyamoto Y, Akaike T, Yoshida M, Goto S, Horie H, and Maeda H (1996) Potentiation of nitric oxide-mediated vasorelaxation by xanthine oxidase inhibitors. Proc Soc Exp Biol Med 211:366-373.
252. Montor SG, Thoolen MJ, Mackin WM, and Timmermans PB (1987) Effect of azapropazone and allopurinol on myocardial infarct size in rats. Eur J Pharmacol 140:203-207.
253. Mori H, Arai T, Ishii H, Adachi T, Endo N, Makino K, and Mori K (1998) Neuroprotective effects of pterin-6-aldehyde in gerbil global brain ischemia: comparison with those of α-phenyl-N-tert-butyl nitrone. Neurosci Lett 241:99-102.
254. Motoe M and Yoshida S (1991) A useful canine model of ischemic myocardium with coronary retrograde flow diversion and its application for the study of allopurinol on myocardial infarct size. Jpn Circ J 55:490-499.
255. Moumen R, Ait-Oukhatar N, Bureau F, Fleury C, Bougle D, Arhan P, Neuville D, and Viader F (2001) Aluminium increases xanthine oxidase activity and disturbs antioxidant status in the rat. J Trace Elem Med Biol 15:89-93.
256. Mugge A, Brandes RP, Boger RH, Dwenger A, Bode-Boger S, Kienke S, Frolich JC, and Lichtlen PR (1994) Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 24:994-998.
257. Myers CL, Weiss SJ, Kirsh MM, Shepard BM, and Shlafer M (1986) Effects of supplementing hypothermic crystalloid cardioplegic solution with catalase, superoxide dismutase, allopurinol, or deferoxamine on functional recovery of globally ischemic and reperfused isolated hearts. J Thorac Cardiovasc Surg 91:281-289.
258. Naito S, Nishimura M, and Tamao Y (2000) Evaluation of the pharmacological actions and pharmacokinetics of BOF-4272, a xanthine oxidase inhibitor, in mouse liver. J Pharm Pharmacol 52:173-179.
259. Nakashima M, Niwa M, Iwai T, and Uematsu T (1999) Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. Free Radic Biol Med 26:722-729.
260. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, and Inoue M (1991) Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 88:10045-10048.
261. Naumova AV, Chacko VP, Ouwerkerk R, Stull L, Marban E, and Weiss RG (2006) Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol 290:H837-H843.
262. Nemeth I, Talosi G, Papp A, and Boda D (2002) Xanthine oxidase activation in mild gestational hypertension. Hypertens Pregnancy 21:1-11.
263. Niederau C, Niederau M, Borchard F, Ude K, Luthen R, Strohmeyer G, Ferrell LD, and Grendell JH (1992) Effects of antioxidants and free radical scavengers in three different models of acute pancreatitis. Pancreas 7:4864-4896.
264. Nielsen VG, Weinbroum A, Tan S, Samuelson PN, Gelman S, and Parks DA (1994) Xanthine oxidoreductase release after descending thoracic aorta occlusion and reperfusion in rabbits. J Thorac Cardiovasc Surg 107:1222-1227.
265. Nilsson UA, Schoenberg MH, Aneman A, Poch B, Magadum S, Beger HG, and Lundgren O (1994) Free radicals and pathogenesis during ischemia and reperfusion of the cat small intestine. Gastroenterology 106:629-636.
266. Nishino T (1994) The conversion of xanthine dehydrogenase to xanthine oxidase and the role of the enzyme in reperfusion injury. J Biochem (Tokyo) 116:1-6.
267. Nishino T, Nakanishi S, Okamoto K, Mizushima J, Hori H, Iwasaki T, Nishino T, Ichimori K, and Nakazawa H (1997) Conversion of xanthine dehydrogenase into oxidase and its role in reperfusion injury. Biochem Soc Trans 25:783-786.
268. Nishino T, Okamoto K, Kawaguchi Y, Hori H, Matsumura T, Eger BT, Pai EF, and Nishino T (2005) Mechanism of conversion of xanthine dehydrogenase to xanthine oxidase: Identification of the two cysteine disulfide bonds and crystal structure of a non-convertible rat liver xanthine dehydrogenase mutant. J Biol Chem 280: 24888-24894.
269. Nishizawa J, Nakai A, Matsuda K, Komeda M, Ban T, and Nagata K (1999) Reactive oxygen species play an important role in the activation of heat shock factor 1 in ischemic-reperfused heart. Circulation 99:934-941.
270. Nivorozhkin A, Mabley J, Pacher P, Southan GJ, Szabó C, and Salzman AL (2003a) A novel xanthine oxidase inhibitor, AN-01-24, protects against development of colitis in mice. FASEB J 17:A265.
271. Nivorozhkin A, Mabley JG, Pacher P, Li H, Southan GJ, Szabó C, and Salzman AL (2003b) A novel class of potent non-purine based xanthine oxidase inhibitors: antihyperuricemic and hepatoprotective effects. FASEB J 17:A253.
272. Novotny MJ, Laughlin MH, and Adams HR (1988) Evidence for lack of importance of oxygen free radicals in Escherichia coli endotoxemia in dogs. Am J Physiol 254: H954-H962.
273. +)-induced hydroxyl radical generation in rat striatum. Neurosci Lett 1-2:9-12.
274. Obrosova IG, Pacher P, Szabó C, Zsengeller Z, Hirooka H, Stevens MJ, and Yorek MA (2005) Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 1:234-242.
275. O'Driscoll JG, Green DJ, Rankin JM, and Taylor RR (1999) Nitric oxide-dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects. Clin Exp Pharmacol Physiol 26:779-783.
276. Oei HH, Stroo WE, Burton KP, and Schaffer SW (1982) A possible role of xanthine oxidase in producing oxidative stress in the heart of chronically ethanol treated rats. Res Commun Chem Pathol Pharmacol 38:453-461.
277. Ohara Y, Peterson TE, and Harrison DG (1993) Hypercholesterolemia increases endothelial superoxide anion production. J Clin Investig 91:2546-2551.
278. Okada K, Yamashita C, Okada M, and Okada M (1995) Successful 24-hour rabbit heart preservation by hypothermic continuous coronary microperfusion with oxygenated University of Wisconsin solution. Ann Thorac Surg 60:1723-1728.
279. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, and Nishino T (2003) An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 278:1848-1855.
280. Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, and Nishino T (2004) The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci USA 101:7931-7936.
281. Okuda M, Furuhashi K, Nakai Y, and Muneyuki M (1993) Decrease of ischaemia-reperfusion related lung oedema by continuous ventilation and allopurinol in rat perfusion lung model. Scand J Clin Lab Investig 53:625-631.
282. Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, Paller MS, and Hebbel RP (2000) Reperfusion injury pathophysiology in sickle transgenic mice. Blood 96: 314-320.
283. Owens ML, Lazarus HM, Wolcott MW, Maxwell JG, and Taylor JB (1974) Allopurinol and hypoxanthine pretreatment of canine kidney donors. Transplantation 17:424-427.
284. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabó E, Ungvari Z, Wolin MS, et al. (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107:896-904.
285. Pacher P, Liaudet L, Mabley J, Komjati K, and Szabó C (2002a) Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart. J Am Coll Cardiol 40:1006-1016.
286. Pacher P, Mabley JG, Soriano FG, Liaudet L, Komjati K, and Szabó C (2002b) Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Br J Pharmacol 135:1347-1350.
287. Pacher P, Obrosova IG, Mabley JG, and Szabó C (2005a) Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications: emerging new therapeutical strategies. Curr Med Chem 12:267-275.
288. Pacher P, Schulz R, Liaudet L, and Szabó C (2005b) Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26:302-310.
289. Page S, Powell D, Benboubetra M, Stevens CR, Blake DR, Selase F, Wolstenholme AJ, and Harrison R (1998) Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. Biochim Biophys Acta 1381:191-202.
290. Pal B, Foxall M, Dysart T, Carey F, and Whittaker M (2000) How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 19:21-25.
291. Palmer C, Towfighi J, Roberts RL, and Heitjan DF (1993) Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7-day-old rats. Pediatr Res 33:405-411.
292. Palmer C, Vannucci RC, and Towfighi J (1990) Reduction of perinatal hypoxicischemic brain damage with allopurinol. Pediatr Res 27:332-336.
293. Panus PC, Wright SA, Chumley PH, Radi R, and Freeman BA (1992) The contribution of vascular endothelial xanthine dehydrogenase/oxidase to oxygen-mediated cell injury. Arch Biochem Biophys 294:695-702.
294. Park DA, Bulkley GB, and Granger DN (1983) Role of oxygen free radicals in shock, ischemia and organ preservation. Surgery 94:428-432.
295. Parker JC and Smith EE (1972) Effects of xanthine oxidase inhibition in cardiac arrest. Surgery 71:339-344.
296. Parks DA, Bulkley GB, Granger DN, Hamilton SR, and McCord JM (1982) Ischemic injury in the cat small intestine: role of superoxide radicals. Gastroenterology 82:9-15.
297. Parks DA and Granger DN (1983) Ischemia-induced vascular changes: role of xanthine oxidase and hydroxyl radicals. Am J Physiol 245:G285-G289.
298. Parks DA, Williams TK, and Beckman JS (1988) Conversion of xanthine dehydrogenase to oxidase in ischemic rat intestine: a reevaluation. Am J Physiol 254: G768-G774.
299. Parmley LF, Mufti AG, and Downey JM (1992) Allopurinol therapy of ischemic heart disease with infarct extension. Can J Cardiol 8:280-286.
300. Parra E, Gota R, Gamen A, Moros M, and Azuara M (1995) Granulomatous interstitial nephritis secondary to allopurinol treatment. Clin Nephrol 43:350.
301. Parratt JR and Wainwright CL (1987) Failure of allopurinol and a spin trapping agent N-t-butyl-α-phenyl nitrone to modify significantly ischaemia and reperfusion-induced arrhythmias. Br J Pharmacol 91:49-59.
302. Pascual E (2000) Gout update: from lab to the clinic and back. Curr Opin Rheumatol 12:213-218.
303. Patetsios P, Song M, Shutze WP, Pappas C, Rodino W, Ramirez JA, and Panetta TF (2001) Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol 88:188-191.
304. Patt A, Harken AH, Burton LK, Rodell TC, Piermattei D, Schorr WJ, Parker NB, Berger EM, Horesh IR, Terada LS, et al. (1988) Xanthine oxidase-derived hydrogen peroxide contributes to ischemia reperfusion-induced edema in gerbil brains. J Clin Investig 81:1556-1562.
305. Pea F (2005) Pharmacology of drugs for hyperuricemia: mechanisms, kinetics and interactions. Contrib Nephrol 147:35-46.
306. 2+-sensitizing property of xanthine oxidase inhibitors. Circ Res 83:423-430.
307. Pesonen EJ, Linder N, Raivio KO, Sarnesto A, Lapatto R, Hockerstedt K, Makisalo H, Andersson S (1998) Circulating xanthine oxidase and neutrophil activation during human liver transplantation. Gastroenterology 14:1009-1015.
308. Phillis JW and Lin Y (1991) Oxypurinol reduces ischemic brain injury in the gerbil and rat. Adv Exp Med Biol 309A:343-346.
309. Phillis JW, Perkins LM, Smith-Barbour M, and O'Regan MH (1995) Oxypurinol-enhanced postischemic recovery of the rat brain involves preservation of adenine nucleotides. J Neurochem 64:2177-2184.
310. Pitt RM, McKelvey TG, Saenger JS, Shah AK, Jones HP, Manci EA, and Powell RW (1991) A tungsten-supplemented diet delivered by transplacental and breastfeeding routes lowers intestinal xanthine oxidase activity and affords cytoprotection in ischemia-reperfusion injury to the small intestine. J Pediatr Surg 26:930-935.
311. Poggetti RS, Moore FA, Moore EE, Koeike K, and Banerjee A (1992) Simultaneous liver and lung injury following gut ischemia is mediated by xanthine oxidase. J Trauma 32:723-727.
312. Pritsos CA (2000) Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact 129:195-208.
313. Puett DW, Forman MB, Cates CU, Wilson BH, Hande KR, Friesinger GC, and Virmani R (1987) Oxypurinol limits myocardial stunning but does not reduce infarct size after reperfusion. Circulation 76:678-686.
314. Qayumi AK, Godin DV, Jamieson WR, Ko KM, and Poostizadeh A (1993) Correlation of red cell antioxidant status and heart-lung function in swine pretreated with allopurinol (a model of heart-lung transplantation). Transplantation 56:37-43.
315. Radi R, Rubbo H, Bush K, and Freeman BA (1997) Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes. Arch Biochem Biophys 339:125-135.
316. Radi R, Tan S, Prodanov E, Evans RA, and Parks DA (1992) Inhibition of xanthine oxidase by uric acid and its influence on superoxide radical production. Biochim Biophys Acta 1122:178-182.
317. Rashid MA and William-Olsson G (1991) Influence of allopurinol on cardiac complications in open heart operations. Ann Thorac Surg 52:127-130.
318. Reimer KA and Jennings RB (1985) Failure of the xanthine oxidase inhibitor allopurinol to limit infarct size after ischemia and reperfusion in dogs. Circulation 71:1069-1075.
319. Reynolds MD (1983) Gout and hyperuricemia associated with sickle-cell anemia. Semin Arthritis Rheum 12:404-413.
320. Reynolds PD, Rhenius ST, and Hunter JO (1996) Xanthine oxidase activity is not increased in the colonic mucosa of ulcerative colitis. Aliment Pharmacol Ther 10:737-741.
321. Rhoden E, Pereira-Lima L, Lucas M, Mauri M, Rhoden C, Pereira-Lima JC, Zettler C, Petteffi L, and Bello-Klein A (2000a) The effects of allopurinol in hepatic ischemia and reperfusion: experimental study in rats. Eur Surg Res 32:215-222.
322. Rhoden E, Teloken C, Lucas M, Rhoden C, Mauri M, Zettler C, Bello-Klein A, and Barros E (2000b) Protective effect of allopurinol in the renal ischemia-reperfusion in uninephrectomized rats. Gen Pharmacol 35:189-193.
323. Riaz AA, Schramm R, Sato T, Menger MD, Jeppsson B, and Thorlacius H (2003) Oxygen radical-dependent expression of CXC chemokines regulate ischemia/ reperfusion-induced leukocyte adhesion in the mouse colon. Free Radic Biol Med 35:782-789.
324. Riaz AA, Wan MX, Schafer T, Dawson P, Menger MD, Jeppsson B, and Thorlacius H (2002) Allopurinol and superoxide dismutase protect against leucocyte-endothelium interactions in a novel model of colonic ischaemia-reperfusion. Br J Surg 89:1572-1580.
325. Richard VJ, Murry CE, Jennings RB, and Reimer KA (1990) Oxygen-derived free radicals and postischemic myocardial reperfusion: therapeutic implications. Fundam Clin 4:85-103.
326. Rijhwani A, Sen S, Gunasekaran S, Ponnaiya J, Balasubramanian KA, and Mammen KE (1995) Allopurinol reduces the severity of peritoneal adhesions in mice. J Pediatr Surg 30:533-537.
327. Rinaldo JE, Clark M, Parinello J, and Shepherd VL (1994) Nitric oxide inactivates xanthine dehydrogenase and xanthine oxidase in interferon-γ- stimulated macrophages. Am J Respir Cell Mol Biol 11:625-630.
328. Roberts JA, Kaack MB, and Baskin G (1990) Treatment of experimental pyelonephritis in the monkey. J Urol 143:150-154.
329. Romao MJ, Archer M, Moura I, Moura JJG, LeGall J, Engh R, Schneider M, Hof P, Huber R (1995) Crystal structure of the xanthine oxidase-related aldehyde oxidoreductase from D. gigas. Science (Wash DC) 270:1170-1176, 1995.
330. Rott KT and Agudelo CA (2003) Gout. J Am Med Assoc 289:2857-2860.
331. Rouquette M, Page S, Bryant R, Benboubetra M, Stevens CR, Blake DR, Whish WD, Harrison R, and Tosh D (1998) Xanthine oxidoreductase is asymmetrically localised on the outer surface of human endothelial and epithelial cells in culture. FEBS Lett 426:397-401.
332. Saavedra WF, Paolocci N, St. John ME, Skaf MW, Stewart GC, Xie JS, Harrison RW, Zeichner J, Mudrick D, Marban E, et al. (2002) Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 90:297-304.
333. Saez JC, Ward PH, Gunther B, and Vivaldi E (1984) Superoxide radical involvement in the pathogenesis of burn shock. Circ Shock 12:229-239.
334. Sakakibara Y (1993) Evaluation of the effectiveness of 5′-nucleotidase inhibitor and allopurinol in myocardial ischemia. Jpn Circ J 57:809-816.
335. Salim AS (1992) Role of oxygen-derived free radical scavengers in the management of recurrent attacks of ulcerative colitis: a new approach. J Lab Clin Med 119: 710-717.
336. Sanders SA and Massey V (1999) The thermodynamics of xanthine oxidoreductase catalysis. Antioxid Redox Signal 1:371-379.
337. Sarnesto A, Linder N, and Raivio KO (1996) Organ distribution and molecular forms of human xanthine dehydrogenase/xanthine oxidase protein. Lab Investig 74:48-56.
338. Saugstad OD (1996) Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Pediatrics 98:103-107.
339. Sawa T, Akaike T, and Maeda H (2000) Tyrosine nitration by peroxynitrite formed from nitric oxide and superoxide generated by xanthine oxidase. J Biol Chem 275:32467-32474.
340. Schlesinger N (2004) Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 64:2399-2416.
341. Schoenberg MH and Beger HG (1993) Reperfusion injury after intestinal ischemia. Crit Care Med 21:376-386.
342. Schrader J (1985) Mechanisms of ischemic injury in the heart. Basic Res Cardiol. 80 (Suppl 2):135-139.
343. Sedghi S, Fields JZ, Klamut M, Urban G, Durkin M, Winship D, Fretland D, Olyaee M, and Keshavarzian A (1993) Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut 34:1191-1197.
344. Segal BH, Sakamoto N, Patel M, Maemura K, Klein AS, Holland SM, and Bulkley GB (2000) Xanthine oxidase contributes to host defense against Burkholderia cepacia in the p47(phox-/-) mouse model of chronic granulomatous disease. Infect Immun 68:2374-2378.
345. Sermet A, Tasdemir N, Deniz B, and Atmaca M (2000) Time-dependent changes in superoxide dismutase, catalase, xanthine dehydrogenase and oxidase activities in focal cerebral ischaemia. Cytobios 102:157-172.
346. Sertac A, Bingol F, Aydin S, and Uslu A (1997) Peroxidative damage in sickle-cell erythrocyte ghosts: protective effect of allopurinol. Gen Pharmacol 28:427-428.
347. Shadid M, Moison R, Steendijk P, Hiltermann L, Berger HM, and van Bel F (1998) The effect of antioxidative combination therapy on post hypoxic-ischemic perfusion, metabolism and electrical activity of the newborn brain. Pediatr Res 44:119-124.
348. Shadid M, Van Bel F, Steendijk P, Dorrepaal CA, Moison R, Van der Velde ET, and Baan J (1999) Pretreatment with allopurinol in cardiac hypoxic-ischemic reperfusion injury in newborn lambs exerts its beneficial effect through afterload reduction. Basic Res Cardiol 94:23-30.
349. Shatney CH, MacCarter DJ, and Lillehei RC (1976) Effects of allopurinol, propranolol and methylprednisolone on infarct size in experimental myocardial infarction. Am J Cardiol 37:572-580.
350. Shatney CH, Toledo-Pereyra LH, and Lillehei RC (1980) Experiences with allopurinal in canine endotoxin shock. Adv Shock Res 4:119-137.
351. Shehab AM, Butler R, MacFadyen RJ, and Struthers AD (2001) A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure. Br J Clin Pharmacol 51:329-334.
352. Siems WG, Grune T, Werner A, Gerber G, Buntrock P, and Schneider W (1992) Protective influence of oxypurinol on the trinitrobenzene sulfonic acid (TNB) model of inflammatory bowel disease in rats. Cell Mol Biol 38:189-199.
353. Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, and Hohneker JA (2000) Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 18:1758-1763.
354. Sobey CG, Dalipram RA, Dusting GJ, and Woodman OL (1992) Impaired endothelium-dependent relaxation of dog coronary arteries after myocardial ischaemia and reperfusion: prevention by amlodipine, propranolol and allopurinol. Br J Pharmacol 105:557-562.
355. Sobey CG, Dalipram RA, and Woodman OL (1993) Allopurinol and amlodipine improve coronary vasodilatation after myocardial ischaemia and reperfusion in anaesthetized dogs. Br J Pharmacol 108:342-347.
356. Solaroglu I, Okutan O, Kaptanoglu E, Beskonakli E, and Kilinc K (2005) Increased xanthine oxidase activity after traumatic brain injury in rats. J Clin Neurosci 12:273-275.
357. Sorescu D and Griendling KK (2002) Reactive oxygen species, mitochondria and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 8:132-140.
358. Srivastava M, Chandra D, and Kale RK (2002) Modulation of radiation-induced changes in the xanthine oxidoreductase system in the livers of mice by its inhibitors. Radiat Res 157:290-297.
359. Srivastava M and Kale RK (1999) Effect of radiation on the xanthine oxidoreductase system in the liver of mice. Radiat Res 152:257-264.
360. Star VL and Hochberg MC (1993) Prevention and management of gout. Drugs 45:212-222.
361. Stepp DW, Ou J, Ackerman AW, Welak S, Klick D, and Pritchard KA Jr (2002) Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascular endothelium in situ. Am J Physiol 283:H750-H759.
362. Stewart JR, Crute SL, Loughlin V, Hess ML, and Greenfield LJ (1985) Prevention of free radical-induced myocardial reperfusion injury with allopurinol. J Thorac Cardiovasc Surg 90:68-72.
363. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, and MacDonald TM (2002) Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 87:229-234.
364. Stull LB, Leppo MK, Szweda L, Gao WD, and Marban E (2004) Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 95:1005-1011.
365. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, Suematsu M, Zweifach BW, and Schmid-Schonbein GW (1998) Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci USA 95:4754-4759.
366. Swei A, Lacy F, Delano FA, Parks DA, and Schmid-Schonbein GW (1999) A mechanism of oxygen free radical production in the Dahl hypertensive rat. Microcirculation 6:179-187.
367. Szabó C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, et al. (2002a) Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8:571-580.
368. Szabó C, Pacher P, Zsengeller Z, Vaslin A, Komjati K, Benko R, Chen M, Mabley JG, and Kollai M (2004) Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 10:28-35.
369. Szabó C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, and Veves A (2002b) Poly(ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106:2680-2686.
370. Taggart DP, Young V, Hooper J, Kemp M, Walesby R, Magee P, and Wright JE (1994) Lack of cardioprotective efficacy of allopurinol in coronary artery surgery. Br Heart J 71:177-181.
371. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, and Becker MA (2005) Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 76:1835-1847.
372. Takeyama N, Shoji Y, Ohashi K, and Tanaka T (1996) Role of reactive oxygen intermediates in lipopolysaccharide-mediated hepatic injury in the rat. J Surg Res 60:258-262.
373. Tan S, Gelman S, Wheat JK, and Parks DA (1995) Circulating xanthine oxidase in human ischemia reperfusion. South Med J 88:479-482.
374. Tan S, McAdams M, Royall J, Freeman BA, and Parks DA (1998) Endothelial injury from a circulating mediator following rat liver ischemia. Free Radic Biol Med 24:427-434.
375. Tan S, Radi R, Gaudier F, Evans RA, Rivera A, Kirk KA, and Parks DA (1993a) Physiologic levels of uric acid inhibit xanthine oxidase in human plasma. Pediatr Res 34:303-307.
376. Tan S, Yokoyama Y, Dickens E, Cash TG, Freeman BA, and Parks DA (1993b) Xanthine oxidase activity in the circulation of rats following hemorrhagic shock. Free Radic Biol Med 15:407-414.
377. Terada LS, Dormish JJ, Shanley PF, Leff JA, Anderson BO, and Repine JE (1992) Circulating xanthine oxidase mediates lung neutrophil sequestration after intestinal ischemia-reperfusion. Am J Physiol 263:L394-L401.
378. Terada LS, Piermattei D, Shibao GN, McManaman JL, and Wright RM (1997a) Hypoxia regulates xanthine dehydrogenase activity at pre- and posttranslational levels. Arch Biochem Biophys 348:163-168.
379. Terada LS, Radisavljevic Z, Mahr NN, and Jacobson ED (1997b) Xanthine oxidase decreases production of gut wall nitric oxide. Proc Soc Exp Biol Med 216:410-413.
380. Terada LS, Rubinstein JD, Lesnefsky EJ, Horwitz LD, Leff JA, and Repine JE (1991) Existence and participation of xanthine oxidase in reperfusion injury of ischemic rabbit myocardium. Am J Physiol 260:H805-H810.
381. Terkeltaub RA (1993) Gout and mechanisms of crystal-induced inflammation. Curr Opin Rheumatol 5:510-516.
382. Terkeltaub RA (2003) Clinical practice. Gout. N Engl J Med 349:1647-1655.
383. Tesi RJ, Jaffe BM, McBride G, and Haque S (1996) Human small bowel preservation injury in University of Wisconsin solution. Transplant Proc 28:2609-2610.
384. Toledo-Pereyra LH, Simmons RL, Olson LC, and Najarian JS (1977) Clinical effect of allopurinol on preserved kidneys: a randomized double-blind study. Ann Surg 185:128-131.
385. Truglio JJ, Theis K, Leimkuhler S, Rappa R, Rajagopalan KV, and Kisker C (2002) Crystal structure of the active and alloxanthine-inhibited forms of xanthine dehydrogenase from Rhodobacter capsulatus. Structure 10:115-125.
386. Trujillo M, Alvarez MN, Peluffo G, Freeman BA, and Radi R (1998) Xanthine oxidase-mediated decomposition of S-nitrosothiols. J Biol Chem 273:7828-7834.
387. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, and Little WC (2001) Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 103:750-755.
388. Umezawa K, Akaike T, Fujii S, Suga M, Setoguchi K, Ozawa A, and Maeda H (1997) Induction of nitric oxide synthesis and xanthine oxidase and their roles in the antimicrobial mechanism against Salmonella typhimurium infection in mice. Infect Immun 65:2932-2940.
389. Ungvári Z, Gupte SA, Recchia FA, Bátkai S, and Pacher P (2005) Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vas Pharmacol 3:221-229.
390. Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, Van De Bor M, and Berger HM (1998) Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics and electrical brain activity. Pediatrics 101: 185-193.
391. van der Loo B, Labugger R, Skepper JN, Bachschmid M, Kilo J, Powell JM, Palacios-Callender M, Erusalimsky JD, Quaschning T, Malinski T, et al. (2000) Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 192:1731-1744.
392. Van Steveninck J, Koster JF, and Dubbelman TM (1989) Xanthine oxidase-catalysed oxidation of paracetamol. Biochem J 259:633-637.
393. Vatistas NJ, Snyder JR, Nieto J, Hildebrand SV, Woliner MJ, Harmon FA, Barry SJ, and Drake C (1998) Morphologic changes and xanthine oxidase activity in the equine jejunum during low flow ischemia and reperfusion. Am J Vet Res 59:772-776.
394. Vaughan WG, Horton JW, and Walker PB (1992) Allopurinol prevents intestinal permeability changes after ischemia-reperfusion injury. J Pediatr Surg 27:968-972.
395. Vinten-Johansen J, Chiantella V, Faust KB, Johnston WE, McCain BL, Hartman M, Mills SA, Hester TO, and Cordell AR (1988) Myocardial protection with blood cardioplegia in ischemically injured hearts: reduction of reoxygenation injury with allopurinol. Ann Thorac Surg 45:319-326.
396. Vorbach C, Harrison R, and Capecchi MR (2003) Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends Immunol 24:512-517.
397. Wakatsuki A, Okatani Y, Izumiya C, and Ikenoue N (1999) Effect of ischemia-reperfusion on xanthine oxidase activity in fetal rat brain capillaries. Am J Obstet Gynecol 181:731-735.
398. Wallace KL, Riedel AA, Joseph-Ridge N, and Wortmann R (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31:1582-1587.
399. Wallwork CJ, Parks DA, and Schmid-Schonbein GW (2003) Xanthine oxidase activity in the dexamethasone-induced hypertensive rat. Microvasc Res 66:30-37.
400. Ward PH, Maldonado M, and Vivaldi E (1992) Oxygen-derived free radicals mediate liver damage in rats subjected to tourniquet shock. Free Radic Res Commun 17:313-325.
401. Werns SW, Grum CM, Ventura A, Hahn RA, Ho PP, Towner RD, Fantone JC, Schork MA, and Lucchesi BR (1991) Xanthine oxidase inhibition does not limit canine infarct size. Circulation 83:995-1005.
402. Werns SW, Shea MJ, Mitsos SE, Dysko RC, Fantone JC, Schork MA, Abrams GD, Pitt B, and Lucchesi BR (1986) Reduction of the size of infarction by allopurinol in the ischemic-reperfused canine heart. Circulation 73:518-524.
403. Wexler BC and McMurtry JP (1981) Allopurinol amelioration of the pathophysiology of acute myocardial infarction in rats. Atherosclerosis 39:71-87.
404. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, and Freeman BA (1996) Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci USA 93:8745-8749.
405. Wijnen MH, Vader HL, and Roumen RM (2002) Multi-antioxidant supplementation does not prevent an increase in gut permeability after lower torso ischemia and reperfusion in humans. Eur Surg Res 34:300-305.
406. Wilkins EG, Rees RS, Smith D, Cashmer B, Punch J, Till GO, and Smith DJ Jr (1993) Identification of xanthine oxidase activity following reperfusion in human tissue. Ann Plast Surg 31:60-65.
407. Willgoss DA, Zhang B, Gobe GC, Kadkhodaee M, and Endre ZH (2003) Repetitive brief ischemia: intermittent reperfusion during ischemia ameliorates the extent of injury in the perfused kidney. Ren Fail 25:379-395.
408. Wolkenstein P and Revuz J (1995) Drug-induced severe skin reactions: incidence, management and prevention. Drug Saf 13:56-68.
409. Wortmann RL (2005) Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 17:319-324.
410. Wright RM, Ginger LA, Kosila N, Elkins ND, Essary B, McManaman JL, and Repine JE (2004) Mononuclear phagocyte xanthine oxidoreductase contributes to cytokine-induced acute lung injury. Am J Respir Cell Mol Biol 30:479-490.
411. Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C Jr, Jones P, Bradley A, and Caskey CT (1994) Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci USA 91:742-746.
412. Xia M, Dempski R, and Hille R (1999) The reductive half-reaction of xanthine oxidase: reaction with aldehyde substrates and identification of the catalytically labile oxygen. J Biol Chem 274:3323-3330.
413. Xia Y and Zweier JL (1995) Substrate control of free radical generation from xanthine oxidase in the postischemic heart. J Biol Chem 270:18797-18803.
414. Xu D, Qi L, Guillory D, Cruz N, Berg R, and Deitch EA (1993) Mechanisms of endotoxin-induced intestinal injury in a hyperdynamic model of sepsis. J Trauma 34:676-682.
415. Xu P, LaVallee P, and Hoidal JR (2000) Repressed expression of the human xanthine oxidoreductase gene: E-box and TATA-like elements restrict ground state transcriptional activity. J Biol Chem 275:5918-5926.
416. Yamada I, Fukunari A, Osajima T, Kamezawa M, Mori H, and Iwane J (2004) Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man. Nucleosides Nucleotides Nucleic Acids 23:1123-1125.
417. Yamamoto T (2003) Development antihyperuricemic candidates. Nippon Rinsho 61(Suppl 1):209-212.
418. Yamazaki I, Soma T, Ichikawa Y, Iwai Y, Kondo J, and Matsumoto A (1995) Usefulness of allopurinol for prevention of myocardial reperfusion injury in open heart surgery. Nippon Kyobu Geka Gakkai Zasshi 43:26-31.
419. Yang CS, Tsai PJ, Chou ST, Niu YL, Lai JS, and Kuo JS (1995) The roles of reactive oxygen species and endogenous opioid peptides in ischemia-induced arrhythmia of isolated rat hearts. Free Radic Biol Med 18:593-598.
420. Yee SB and Pritsos CA (1997) Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin and menadione by xanthine oxidase and xanthine dehydrogenase. Arch Biochem Biophys 347:235-241.
421. Yildirim S, Tok H, Koksal H, Erdem L, and Baykan A (2002) Allopurinol plus pentoxifilline in hepatic ischaemia/reperfusion injury. Asian J Surg 25:149-153.
422. Yokoyama Y, Beckman JS, Beckman TK, Wheat JK, Cash TG, Freeman BA, and Parks DA (1990) Circulating xanthine oxidase: potential mediator of ischemic injury. Am J Physiol 258:G564-G570.
423. Yossif AM, Ibrahim TM, Salem HA, Gamil NM, and el-Sayed LM (1995) Effect of high lipid diet and allopurinol on the development of experimentally induced arthritis in rats. Pharmacology 51:160-164.
424. Zeki S, Miura S, Suzuki H, Watanabe N, Adachi M, Yokoyama H, Horie Y, Saito H, Kato S, and Ishii H (2002) Xanthine oxidase-derived oxygen radicals play significant roles in the development of chronic pancreatitis in WBN/Kob rats. J Gastroenterol Hepatol 17:606-616.
425. Zhang Z, Blake DR, Stevens CR, Kanczler JM, Winyard PG, Symons MC, Benboubetra M, and Harrison R (1998a) A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor. Free Radic Res 28:151-164.
426. Zhang Z, Naughton D, Winyard PG, Benjamin N, Blake DR, and Symons MC (1998b) Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun 249:767-772.
427. Zima T, Fialova L, Mestek O, Janebova M, Crkovska J, Malbohan I, Stipek S, Mikulikova L, and Popov P (2001) Oxidative stress, metabolism of ethanol and alcohol-related diseases. J Biomed Sci 8:59-70.
428. Zima T, Novak L, and Stipek S (1993) Plasma xanthine oxidase level and alcohol administration. Alcohol Alcohol 28:693-694.